The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SKYE | -71.12% | -84.61% | -31.21% | -100% |
| S&P | +17.35% | +108.64% | +15.84% | +229% |
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. It focuses on the treatment of a spectrum of diseases, as well as utilizing bioengineering in drug design. Its product pipeline includes SBI-100 and SBI-200. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.19M | -527.9% |
| Market Cap | $129.51M | -42.4% |
| Market Cap / Employee | $8.09M | 0.0% |
| Employees | 16 | 45.5% |
| Net Income | -$17.62M | -123.0% |
| EBITDA | -$18.06M | -115.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $23.84M | -71.3% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.17M | 32.8% |
| Short Term Debt | $0.20M | -96.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -60.78% | 33.7% |
| Return On Invested Capital | 407.47% | -30.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10.75M | -50.8% |
| Operating Free Cash Flow | -$10.75M | -51.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.51 | 1.13 | 0.72 | 2.19 | -23.32% |
| Price to Tangible Book Value | 1.51 | 1.13 | 0.72 | 2.19 | -23.32% |
| Enterprise Value to EBITDA | -7.98 | -3.71 | -0.37 | -6.51 | -76.46% |
| Return on Equity | -54.8% | -80.5% | -47.3% | -72.8% | -44.07% |
| Total Debt | $0.19M | $0.46M | $0.41M | $0.37M | -92.75% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
